Bristol-Myers Squibb now has one less headache to worry about involving its Plavix blood-thinner product, one of the most prescribed medications in the world. In a Securities and Exchange filing last week, the company revealed that in May, it agreed to pay $125 million to settle a securities class action that alleged BMS and its former chief executive violated securities laws by hiding material information about their efforts to settle a patent lawsuit with the Canadian generic drug maker Apotex Inc.

By way of background, in 2002, Apotex challenged Bristol-Myers’ Plavix patent, as per Hatch-Waxman procedure. In 2006, Bristol-Myers entered into negotiations with Apotex to settle the patent dispute. A tentative settlement agreement fell apart and Apotex briefly sold generic Plavix in the United States before a federal judge ordered it to stop. BMS eventually prevailed in the patent case, but Plavix sales suffered.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]